Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes.

Antidote GABA Indications benzodiazepine contraindications flumazenil overdose poisoning treatment

Journal

Expert opinion on drug metabolism & toxicology
ISSN: 1744-7607
Titre abrégé: Expert Opin Drug Metab Toxicol
Pays: England
ID NLM: 101228422

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 26 7 2022
medline: 11 8 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Although not a potentially life-threatening poisoning, benzodiazepine (BZD) intoxication may be life-threatening in special situations/populations or those with background diseases. The aim of this review is to evaluate all possible treatment options available in the literature for the management of benzodiazepine poisoning with special attention to antidote administration. We conducted a literature search using PubMed, Google Scholar, EMBASE, and Cochrane central register from 1 January 1980 to 10 November 2021 using keywords 'benzodiazepine,' 'poisoning,' 'toxicity,' 'intoxication,' and 'treatment.' Careful patient selection, ideally by a clinical toxicologist, may decrease the complications of flumazenil and add to its efficacy. The cost-to-benefit ratio should be considered in every single patient who is a candidate for flumazenil administration. In case a decision has been made to administer flumazenil, careful consideration of the possible contraindications is essential. We recommend slow administration of low doses of flumazenil (0.1 mg/minute) to avoid complications or withhold the administration with development of first signs of adverse effects. The main treatment of benzodiazepine toxicity is conservative with administration of activated charcoal, monitoring of the vital signs, prevention of aspiration and development of deep vein thrombosis due to prolonged immobilization, and respiratory support.

Identifiants

pubmed: 35875992
doi: 10.1080/17425255.2022.2105692
doi:

Substances chimiques

Antidotes 0
Benzodiazepines 12794-10-4
Flumazenil 40P7XK9392

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-379

Auteurs

Nasim Zamani (N)

Department of Clinical Toxicology, Loghman-Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Social Determinants Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hossein Hassanian-Moghaddam (H)

Department of Clinical Toxicology, Loghman-Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Social Determinants Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Naghmeh Zamani (N)

Department of Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH